$VYGR
Voyager Therapeutics, Inc.

2022 Q3 Form 10-Q Financial Statement

#000155837022012267 Filed on August 04, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $41.09M $712.0K $658.0K
YoY Change 2672.33% -47.53% -89.88%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.307M $7.552M $7.659M
YoY Change -16.15% -27.64% -21.04%
% of Gross Profit
Research & Development $19.34M $12.53M $14.35M
YoY Change 7.94% -35.78% -35.79%
% of Gross Profit
Depreciation & Amortization $1.341M $1.204M $2.812M
YoY Change 9.56% 3.88% 120.72%
% of Gross Profit
Operating Expenses $26.64M $20.08M $22.01M
YoY Change 0.06% -32.94% -31.42%
Operating Profit $14.44M -$19.37M -$21.35M
YoY Change -157.43% -32.25% -16.57%
Interest Expense $545.0K $219.0K $31.00K
YoY Change 350.41% 356.25% 63.16%
% of Operating Profit 3.77%
Other Income/Expense, Net $3.182M $280.0K $31.00K
YoY Change 35255.56% -118.24% -99.21%
Pretax Income $17.62M -$19.09M -$21.32M
YoY Change -170.11% -36.63% -1.3%
Income Tax
% Of Pretax Income
Net Earnings $17.62M -$19.09M -$21.32M
YoY Change -170.11% -36.63% -1.52%
Net Earnings / Revenue 42.9% -2680.76% -3239.97%
Basic Earnings Per Share $0.46 -$0.50 -$0.56
Diluted Earnings Per Share $0.45 -$0.50 -$0.56
COMMON SHARES
Basic Shares Outstanding 38.65M 38.30M 38.05M
Diluted Shares Outstanding 39.57M 38.30M 38.05M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $131.6M $148.1M $166.8M
YoY Change 8.34% 3.55% 3.3%
Cash & Equivalents $96.86M $78.33M $131.9M
Short-Term Investments $34.78M $69.73M $34.96M
Other Short-Term Assets $5.079M $3.421M $3.612M
YoY Change 43.47% -12.51% -64.24%
Inventory
Prepaid Expenses
Receivables $10.23M $151.0K $206.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $146.9M $151.6M $170.7M
YoY Change 16.43% 2.0% -2.95%
LONG-TERM ASSETS
Property, Plant & Equipment $18.08M $19.07M $19.37M
YoY Change -21.36% -19.49% -20.99%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.515M $1.515M $1.779M
YoY Change -14.84% -32.58% -19.14%
Total Long-Term Assets $35.54M $36.98M $53.53M
YoY Change -39.32% -38.45% -13.49%
TOTAL ASSETS
Total Short-Term Assets $146.9M $151.6M $170.7M
Total Long-Term Assets $35.54M $36.98M $53.53M
Total Assets $182.5M $188.6M $224.2M
YoY Change -1.24% -9.64% -5.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.337M $1.218M $1.200M
YoY Change 125.84% 54.18% -62.23%
Accrued Expenses $12.53M $7.185M $7.735M
YoY Change 10.64% -34.44% -26.58%
Deferred Revenue $56.63M $87.00M $86.99M
YoY Change 493.79% 978.24% 1250.21%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $73.24M $97.93M $101.7M
YoY Change 174.3% 296.68% 310.8%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $22.02M $22.74M $38.13M
YoY Change -46.3% -45.66% -11.63%
Total Long-Term Liabilities $22.02M $22.74M $38.13M
YoY Change -46.3% -45.66% -11.63%
TOTAL LIABILITIES
Total Short-Term Liabilities $73.24M $97.93M $101.7M
Total Long-Term Liabilities $22.02M $22.74M $38.13M
Total Liabilities $102.7M $128.6M $148.3M
YoY Change 5.45% 30.92% 46.05%
SHAREHOLDERS EQUITY
Retained Earnings -$369.9M -$387.5M -$368.4M
YoY Change 4.85% 18.25% 23.79%
Common Stock $38.00K $38.00K $38.00K
YoY Change 0.0% 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $79.82M $60.05M $75.93M
YoY Change
Total Liabilities & Shareholders Equity $182.5M $188.6M $224.2M
YoY Change -1.24% -9.64% -5.69%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income $17.62M -$19.09M -$21.32M
YoY Change -170.11% -36.63% -1.52%
Depreciation, Depletion And Amortization $1.341M $1.204M $2.812M
YoY Change 9.56% 3.88% 120.72%
Cash From Operating Activities -$16.21M -$18.49M $34.43M
YoY Change -21.74% -18.61% -261.67%
INVESTING ACTIVITIES
Capital Expenditures -$278.0K -$1.242M $38.00K
YoY Change -57.88% 514.85% -89.87%
Acquisitions
YoY Change
Other Investing Activities $35.00M -$34.89M -$19.96M
YoY Change 133.33% -254.15% -157.03%
Cash From Investing Activities $34.72M -$36.13M -$20.00M
YoY Change 142.13% -261.08% -157.76%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 15.00K 807.0K 12.00K
YoY Change 109.61% -57.14%
NET CHANGE
Cash From Operating Activities -16.21M -18.49M 34.43M
Cash From Investing Activities 34.72M -36.13M -20.00M
Cash From Financing Activities 15.00K 807.0K 12.00K
Net Change In Cash 18.53M -53.81M 14.44M
YoY Change -390.96% -51838.46% 8.09%
FREE CASH FLOW
Cash From Operating Activities -$16.21M -$18.49M $34.43M
Capital Expenditures -$278.0K -$1.242M $38.00K
Free Cash Flow -$15.93M -$17.24M $34.39M
YoY Change -20.55% -23.4% -258.7%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
CY2021Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.50
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.80
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.06
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.38
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38298426
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37581381
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38183192
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37543387
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38439251
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001640266
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37918395
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37625
dei Entity Registrant Name
EntityRegistrantName
Voyager Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-3003182
dei Entity Address Address Line1
EntityAddressAddressLine1
64 Sidney Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
259-5340
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
VYGR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
38647592
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
78329000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
117433000
CY2022Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
69727000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
15106000
CY2022Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
151000
CY2021Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
732000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3421000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3427000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
151628000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21920000
CY2022Q2 vygr Deposits And Other Non Current Assets
DepositsAndOtherNonCurrentAssets
1515000
CY2022Q2 us-gaap Assets
Assets
188605000
CY2021Q4 us-gaap Assets
Assets
193855000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
136698000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19071000
CY2021Q4 vygr Deposits And Other Non Current Assets
DepositsAndOtherNonCurrentAssets
1779000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
16391000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
33458000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1218000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
574000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7185000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10950000
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2526000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5571000
CY2022Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
87003000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
33886000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
97932000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
50981000
CY2022Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
7880000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
8210000
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
22741000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
39609000
CY2022Q2 us-gaap Liabilities
Liabilities
128553000
CY2021Q4 us-gaap Liabilities
Liabilities
98800000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38439251
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37918395
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
38000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
38000
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
447888000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
442259000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-364000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-138000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-387510000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-347104000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
60052000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
95055000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
188605000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
193855000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
712000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1357000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1371000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7858000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12527000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19505000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26876000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
41851000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7552000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10437000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15211000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20181000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
20079000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
29942000
us-gaap Operating Expenses
OperatingExpenses
42087000
us-gaap Operating Expenses
OperatingExpenses
62032000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-19367000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-28585000
us-gaap Operating Income Loss
OperatingIncomeLoss
-40716000
us-gaap Operating Income Loss
OperatingIncomeLoss
-54174000
CY2022Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
219000
CY2021Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
48000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
271000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
132000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
61000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1583000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
39000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2273000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
280000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1535000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
310000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2405000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-19087000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-30120000
us-gaap Net Income Loss
NetIncomeLoss
-40406000
us-gaap Net Income Loss
NetIncomeLoss
-51769000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-141000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-226000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
8000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-141000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-3000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-226000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
8000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19228000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30123000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40632000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-51761000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.50
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.80
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.38
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38298426
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37581381
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38183192
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37543387
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
154320000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
28000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3498000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
602000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
136208000
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
580000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
11000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-21649000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3871000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-30120000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
110536000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
95055000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
12000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2268000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-85000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-21319000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
75931000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
575000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
313000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2460000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-141000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-19087000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
60052000
us-gaap Profit Loss
ProfitLoss
-40406000
us-gaap Profit Loss
ProfitLoss
-51769000
us-gaap Share Based Compensation
ShareBasedCompensation
4809000
us-gaap Share Based Compensation
ShareBasedCompensation
7592000
us-gaap Depreciation
Depreciation
4016000
us-gaap Depreciation
Depreciation
2459000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-2000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-213000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
2469000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
2460000
vygr Increase Decrease In Collaboration Receivables
IncreaseDecreaseInCollaborationReceivables
-581000
vygr Increase Decrease In Collaboration Receivables
IncreaseDecreaseInCollaborationReceivables
-6254000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-6000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-893000
vygr Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
-2556000
vygr Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
-1922000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-69000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
644000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
156000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3652000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3357000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2647000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1891000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-287000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
52787000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-4092000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
15941000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-44011000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1280000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
54848000
vygr Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
57632000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
232000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-56128000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
57030000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
587000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
28000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
357000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
819000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
385000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-39368000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
13404000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
119212000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
106219000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
79844000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
119623000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
113000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
111000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Nature of business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Voyager Therapeutics, Inc. (the “Company”) is a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (“AAV”) capsids. The Company focuses on diseases where it believes a single dose AAV gene therapy or an antibody can either halt or slow disease progression or reduce symptom severity, therefore providing clinically meaningful impact to patients. The Company’s gene therapy platforms enable it to engineer, optimize, manufacture and deliver its AAV-based gene therapies that it believes have the potential to safely provide durable efficacy. The Company’s team of experts in the field of AAV gene therapy and neuroscience first identifies and selects diseases in which the Company believes an AAV gene therapy or an antibody will answer a high unmet medical need, be supported by target validation, offer an efficient path to human proof of biology, present robust preclinical pharmacology, and offer strong commercial potential. The Company then engineers and optimizes either an AAV vector for delivery of the virus payload to the targeted tissue or cells or a passive antibody for systemic delivery. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is identifying proprietary AAV capsids, the outer viral protein shells that enclose genetic material of a virus payload. The Company’s team has developed a proprietary AAV capsid discovery platform called TRACER<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> (Tropism Redirection of AAV by Cell Type-Specific Expression of RNA) to facilitate the selection of AAV capsids with blood brain barrier (“BBB”) crossing and cell-specific transduction properties for particular therapeutic applications. The TRACER discovery platform is a broadly applicable, functional RNA-based AAV capsid discovery platform that allows for rapid <i style="font-style:italic;">in vivo</i> evolution of AAV capsids with cell-specific transduction properties in multiple species, including non-human primates. The Company believes its single dose gene therapies have the potential to be delivered with targeted or systemic surgical delivery or infusions, in conjunction with capsids it discovers through its TRACER platform (“TRACER capsids”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is also applying the TRACER discovery platform to identify capsid variant libraries and facilitate the selection of capsids with tropism and transduction in additional cell and tissue types. The Company is actively engaged in discussions with multiple parties to make TRACER capsids available to third parties for use in their drug development programs through potential licensing and other arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to the Company’s TRACER discovery platform, the Company has developed a vectorized antibody platform which the Company believes will overcome many of the challenges of passive immunization. However, the Company has also seen promising preclinical results from the passive immunization approach and the Company is investigating both passive immunization and vectorized approaches to administer proprietary antibodies that selectively target pathological tau to address tauopathies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s business strategy focuses on discovering, developing, manufacturing and commercializing its gene therapy and antibody programs. As part of this strategy, the Company has developed core competencies specific to AAV gene therapy and antibody development and manufacturing. This business strategy also includes business development activities that may include in-licensing activities or partnering certain programs in specific geographies with collaborators, as the Company has demonstrated through its ongoing <span style="background:#ffffff;">collaboration with Neurocrine Biosciences, Inc. (“Neurocrine”) under a collaboration agreement that became effective in January 2019 (the “Neurocrine Collaboration Agreement”), or out-licensing activities including license agreements related to the TRACER capsids such as the Company’s October 2021 licensing agreement with Pfizer Inc. </span>(“Pfizer”) and the Company’s March 2022 licensing agreement with Novartis Pharma AG (“Novartis”). The Company believes there is an ongoing opportunity for out-licensing transactions related to the TRACER capsids. To maximize the potential of TRACER capsids for the Company’s own programs and out-licensing transactions, the Company has retained to date, and expects to retain in the future, all rights associated with such TRACER capsids other than the rights specific to their use in combination with a particular licensee’s transgenes. <span style="background:#ffffff;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is devoting substantially all of its efforts to product research and development, market development, and raising capital. The Company is subject to risks common to companies in the biotechnology and gene therapy industries, including but not limited to, the need to obtain sufficient capital to continue to fund its operations, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for its product candidates, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary information and technology, protection against data breaches and other cybersecurity threats, compliance with government regulations, development by competitors of technological innovations, and ability to transition from pilot-scale manufacturing to large-scale production of products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has a history of incurring annual net operating losses. As of June 30, 2022, the Company had an accumulated deficit of $387.5 million. The Company has not generated any product revenue and has financed its operations primarily through public offerings and private placements of its equity securities and funding from fees, milestone payments, and cost reimbursements associated with its prior collaborations with Sanofi Genzyme Corporation (“Sanofi Genzyme”) and AbbVie Biotechnology Ltd and AbbVie Ireland Unlimited Company (collectively, “AbbVie”), and its ongoing collaboration with Neurocrine, <span style="font-family:'Times';">its licensing agreement with Pfizer, and its licensing agreement with Novartis.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Through June 30, 2022, the Company has raised approximately $724.0 million of proceeds from sales of convertible preferred stock and common stock, including its initial public offering and follow-on public offering, and from its collaboration and license agreements. As of June 30, 2022, the Company had cash, cash equivalents, and marketable securities of $148.1 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based upon its current operating plan, the Company expects that its existing cash, cash equivalents, and marketable securities at June 30, 2022, together with amounts expected to be received as reimbursement for development costs under the Neurocrine Collaboration Agreement, will be sufficient to meet the Company’s planned operating expenses and capital expenditure re<span style="background:#ffffff;">quirements</span> into 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There can be no assurance that the Company will be able to obtain additional debt or equity financing on terms acceptable to the Company or generate product revenue or revenue from collaboration partners, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations, and financial condition. </p>
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-387500000
CY2022Q2 vygr Proceeds From Issuance Of Equity And Collaboration Agreements
ProceedsFromIssuanceOfEquityAndCollaborationAgreements
724000000.0
CY2022Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
148100000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Use of Estimates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not limited to, estimates related to revenue recognition, accrued expenses, stock-based compensation expense, and income taxes. The Company bases its estimates on historical experience and other market specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. Certain reclassifications have been made to prior periods to conform to current period presentation.</p>
CY2022Q2 vygr Money Market Funds And Marketable Securities Amortized Cost Basis
MoneyMarketFundsAndMarketableSecuritiesAmortizedCostBasis
145524000
CY2022Q2 vygr Money Market Funds And Marketable Securities Gross Unrealized Loss Before Tax
MoneyMarketFundsAndMarketableSecuritiesGrossUnrealizedLossBeforeTax
236000
CY2022Q2 vygr Money Market Funds And Marketable Securities Fair Value
MoneyMarketFundsAndMarketableSecuritiesFairValue
145288000
CY2021Q4 vygr Money Market Funds And Marketable Securities Amortized Cost Basis
MoneyMarketFundsAndMarketableSecuritiesAmortizedCostBasis
115422000
CY2021Q4 vygr Money Market Funds And Marketable Securities Gross Unrealized Loss Before Tax
MoneyMarketFundsAndMarketableSecuritiesGrossUnrealizedLossBeforeTax
11000
CY2021Q4 vygr Money Market Funds And Marketable Securities Fair Value
MoneyMarketFundsAndMarketableSecuritiesFairValue
115411000
CY2022Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
70000000.0
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
15100000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
78329000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
117433000
CY2022Q2 us-gaap Restricted Cash
RestrictedCash
1515000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
1779000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
79844000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
119212000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2800000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5022000
CY2022Q2 vygr Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
3662000
CY2021Q4 vygr Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
3719000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
344000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
727000
CY2022Q2 vygr Accrued Goods And Services Current
AccruedGoodsAndServicesCurrent
379000
CY2021Q4 vygr Accrued Goods And Services Current
AccruedGoodsAndServicesCurrent
1482000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7185000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10950000
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
1400000
us-gaap Operating Lease Expense
OperatingLeaseExpense
2800000
CY2021Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
1900000
us-gaap Operating Lease Expense
OperatingLeaseExpense
3700000
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y6M
CY2022Q2 vygr Operating Lease Weighted Average Incremental Borrowing Rate
OperatingLeaseWeightedAverageIncrementalBorrowingRate
0.074
CY2022Q2 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
690000
us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
1380000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2526000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5571000
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2526000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5571000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
21741000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
38608000
CY2022Q2 vygr Miscellaneous Other Liabilities Noncurrent
MiscellaneousOtherLiabilitiesNoncurrent
1000000
CY2021Q4 vygr Miscellaneous Other Liabilities Noncurrent
MiscellaneousOtherLiabilitiesNoncurrent
1001000
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
22741000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
39609000
CY2021 us-gaap Restructuring Costs
RestructuringCosts
2600000
CY2021Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
732000
vygr Additions To Contract With Customer Assets
AdditionsToContractWithCustomerAssets
358000
vygr Deductions To Contract With Customer Assets
DeductionsToContractWithCustomerAssets
939000
CY2022Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
151000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
12096000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1214000
CY2022Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
10881000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2490000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3991000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4809000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7592000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2490000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3991000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4809000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7592000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5013193
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.69
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y7M6D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1165000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2965075
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.95
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
74496
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.90
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
1274172
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
12.42
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6629600
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.33
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M12D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
5914000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3378945
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
12.29
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y3M18D
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1575000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7798220
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7246940

Files In Submission

Name View Source Status
0001558370-22-012267-index-headers.html Edgar Link pending
0001558370-22-012267-index.html Edgar Link pending
0001558370-22-012267.txt Edgar Link pending
0001558370-22-012267-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vygr-20220630.xsd Edgar Link pending
vygr-20220630x10q.htm Edgar Link pending
vygr-20220630x10q006.jpg Edgar Link pending
vygr-20220630x10q_htm.xml Edgar Link completed
vygr-20220630xex31d1.htm Edgar Link pending
vygr-20220630xex31d2.htm Edgar Link pending
vygr-20220630xex32d1.htm Edgar Link pending
vygr-20220630_cal.xml Edgar Link unprocessable
vygr-20220630_def.xml Edgar Link unprocessable
vygr-20220630_lab.xml Edgar Link unprocessable
vygr-20220630_pre.xml Edgar Link unprocessable